Seikagaku and partner Ono Pharmaceutical announced approval from the Japan Ministry of Health, Labour and Welfare for manufacturing and marketing of JOYCLU® to treat hip and knee osteoarthritis.
JOYCLU combines hyaluronic acid and the anti-inflammatory drug diclofenac, administered by injection into the joint cavity once every four weeks. JOYCLU is the first joint function improvement agent in Japan indicated for the treatment of osteoarthritis of the hip joint.
Seikagaku will manufacture and market the product, and Ono will be responsible for distribution.
Seikagaku and partner Ono Pharmaceutical announced approval from the Japan Ministry of Health, Labour and Welfare for manufacturing and marketing of JOYCLU® to treat hip and knee osteoarthritis.
JOYCLU combines hyaluronic acid and the anti-inflammatory drug diclofenac,...
Seikagaku and partner Ono Pharmaceutical announced approval from the Japan Ministry of Health, Labour and Welfare for manufacturing and marketing of JOYCLU® to treat hip and knee osteoarthritis.
JOYCLU combines hyaluronic acid and the anti-inflammatory drug diclofenac, administered by injection into the joint cavity once every four weeks. JOYCLU is the first joint function improvement agent in Japan indicated for the treatment of osteoarthritis of the hip joint.
Seikagaku will manufacture and market the product, and Ono will be responsible for distribution.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
